Catalyst Pharmaceuticals, Inc. (CPRX): Price and Financial Metrics
CPRX Stock Summary
- CPRX's current price/earnings ratio is 6.27, which is higher than merely 4.93% of US stocks with positive earnings.
- The ratio of debt to operating expenses for Catalyst Pharmaceuticals Inc is higher than it is for about only 0.3% of US stocks.
- With a year-over-year growth in debt of -100%, Catalyst Pharmaceuticals Inc's debt growth rate surpasses merely 0% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Catalyst Pharmaceuticals Inc are AXTI, NTGR, NIU, FLDM, and ICAD.
- CPRX's SEC filings can be seen here. And to visit Catalyst Pharmaceuticals Inc's official web site, go to www.catalystpharma.com.
CPRX Stock Price Chart Interactive Chart >
CPRX Price/Volume Stats
| Current price | $4.60 | 52-week high | $5.19 |
| Prev. close | $4.53 | 52-week low | $2.88 |
| Day low | $4.42 | Volume | 984,990 |
| Day high | $4.69 | Avg. volume | 1,687,284 |
| 50-day MA | $4.22 | Dividend yield | N/A |
| 200-day MA | $3.77 | Market Cap | 477.60M |
Catalyst Pharmaceuticals, Inc. (CPRX) Company Bio
Catalyst Pharmaceuticals focuses on the development and commercialization of prescription drugs targeting rare neurological diseases and disorders. The company was founded in 2002 and is based in Coral Gables, Florida.
Latest CPRX News From Around the Web
Below are the latest news stories about Catalyst Pharmaceuticals Inc that investors may wish to consider to help them evaluate CPRX as an investment opportunity.
Catalyst Pharma To Buy Back $40M In Stock; Shares Gain Pre-MarketShares of Catalyst Pharma rose more than 3% in the pre-market session after the commercial-stage biopharmaceutical company announced its stock repurchase program of up to $40 million. Catalyst Pharma (CPRX) intends to use existing cash on hand to fund the share repurchase program. Catalyst Pharma CEO Patrick J. McEnany said, “We believe that our strong balance sheet, earnings power and borrowing capability have us well-positioned to successfully execute both on our recently announced strategic initiative to expand our product and pipeline portfolio of therapies to treat other rare diseases and on this share repurchase program.” (See Catalyst Pharma stock analysis on TipRanks) Last week, the company reported 4Q results. |
With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Is InterestingIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks... |
Top Biotech Stocks for Q2 2021The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline. |
Catalyst Pharma 4Q Revenue, Earnings Outperform EstimatesCatalyst Pharmaceuticals delivered a better-than-expected 4Q performance, driven by higher sales for Firdapse, which is used to treat Lambert-Eaton myasthenic syndrome (LEMS) patients. Shares of the commercial stage biopharmaceutical company rose about 1.5% in the extended trading session on Monday. Catalyst Pharma’s (CPRX) revenue, comprised primarily of Firdapse sales, increased by $0.9 million year-over-year to hit $31 million, topping analysts’ estimates of $30.35 million. The company posted adjusted earnings of $0.11 per share, up 57% year-over-year, with the figure exceeding analysts’ expectations of $0.09 per share. The company’s Chairman and CEO Patrick J. McEnany said, “We are extremely pleased with our continued commercial execution of the Firdapse launch during 2020. |
Catalyst Pharmaceuticals, Inc. to Host Earnings CallNEW YORK, NY / ACCESSWIRE / March 16, 2021 / Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 16, 2021 at 8:30 AM Eastern Time. |
CPRX Price Returns
| 1-mo | -1.50% |
| 3-mo | 27.78% |
| 6-mo | 44.20% |
| 1-year | -3.97% |
| 3-year | 79.69% |
| 5-year | 280.17% |
| YTD | 37.72% |
| 2020 | -10.93% |
| 2019 | 95.31% |
| 2018 | -50.90% |
| 2017 | 272.38% |
| 2016 | -57.14% |
Continue Researching CPRX
Want to do more research on Catalyst Pharmaceuticals Inc's stock and its price? Try the links below:Catalyst Pharmaceuticals Inc (CPRX) Stock Price | Nasdaq
Catalyst Pharmaceuticals Inc (CPRX) Stock Quote, History and News - Yahoo Finance
Catalyst Pharmaceuticals Inc (CPRX) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...